STRATA Skin Sciences' Revenue Dips, Losses Widen Amid Macro Headwinds

TL;DR

**SSKN is bleeding cash and revenue, making it a risky bet as macro issues persist.**

AI Summary

STRATA Skin Sciences, Inc. (SSKN) reported a significant decline in revenue and increased net loss for the nine months ended September 30, 2025, compared to the same period in 2024. Net revenues decreased from $23.986 million in 2024 to $21.404 million in 2025, a 10.76% reduction. The net loss widened from $5.531 million in 2024 to $6.319 million in 2025, representing a 14.25% increase in losses. Gross profit also fell from $13.459 million to $12.267 million. Operating expenses saw a slight decrease, primarily due to a $684 thousand settlement gain in 2025, offsetting increases in selling and marketing expenses from $9.215 million to $9.857 million. The company's cash and cash equivalents decreased from $7.261 million at December 31, 2024, to $7.076 million at September 30, 2025. A key business change was the execution of a $1.3 million appellate bond by the State of New York, which was previously held as restricted cash. Risks include ongoing supply chain disruptions for noble gases due to the Russia-Ukraine War and potential impacts from Middle East conflicts and increased tariffs.

Why It Matters

This filing reveals STRATA Skin Sciences is struggling with declining revenues and increasing losses, which directly impacts investor confidence and the company's valuation. The competitive landscape in medical technology, particularly for dermatologic conditions, demands strong financial performance and innovation, areas where SSKN is currently underperforming. Employees might face job insecurity if these trends continue, and customers could see reduced investment in product development or service quality. The broader market for medical devices could view this as a cautionary tale regarding reliance on specific supply chains and the impact of geopolitical events.

Risk Assessment

Risk Level: high — The company's net loss increased by 14.25% to $6.319 million for the nine months ended September 30, 2025, while net revenues decreased by 10.76% to $21.404 million. Furthermore, cash and cash equivalents declined from $7.261 million to $7.076 million, and the $1.3 million restricted cash was executed by the State of New York, indicating significant financial strain and reduced liquidity.

Analyst Insight

Investors should exercise extreme caution and consider divesting SSKN shares given the consistent revenue decline, widening losses, and significant liquidity reduction. Monitor future filings for any signs of revenue stabilization or successful cost-cutting measures before considering any new positions.

Financial Highlights

debt To Equity

22.37

revenue

$21.404M

operating Margin

-30.0%

total Assets

$30.717M

total Debt

$31.318M

net Income

-$6.319M

eps

-$1.48

gross Margin

57.3%

cash Position

$7.076M

revenue Growth

-10.76%

Key Numbers

• $21.404M — Net Revenues (Decreased from $23.986M in 2024 for the nine months ended September 30, 2025)
• $6.319M — Net Loss (Increased from $5.531M in 2024 for the nine months ended September 30, 2025)
• $7.076M — Cash and Cash Equivalents (As of September 30, 2025, down from $7.261M at December 31, 2024)
• $1.3M — Restricted Cash (Executed by the State of New York during the nine months ended September 30, 2025)
• 838 — XTRAC systems (Placed in dermatologists' offices in the United States as of September 30, 2025)
• $0.36 — Net loss per share (For the three months ended September 30, 2025, improved from $0.51 in 2024)
• $1.48 — Net loss per share (For the nine months ended September 30, 2025, slightly improved from $1.50 in 2024)
• $684K — Settlement gains (Recorded in operating expenses for the three and nine months ended September 30, 2025)

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — registrant
• State of New York (regulator) — executed appellate bond for $1.3 million
• The Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• Photomedex India Private Limited (company) — wholly-owned, inactive subsidiary
• United States Food and Drug Administration (regulator) — cleared XTRAC excimer laser system
• Russia-Ukraine War (event) — impacts noble gas supply
• Middle East conflict (event) — potential impact on distributors
• CARES Act (regulator) — Employee Retention Credit

FAQ

Risk Factors

• Declining Revenue and Widening Net Loss [high — financial]: Net revenues decreased by 10.76% from $23.986 million to $21.404 million for the nine months ended September 30, 2025. Concurrently, the net loss widened by 14.25% from $5.531 million to $6.319 million, indicating a deteriorating financial performance.
• Supply Chain Disruptions [medium — operational]: Ongoing supply chain disruptions for noble gases, exacerbated by the Russia-Ukraine War and potential impacts from Middle East conflicts and increased tariffs, pose a significant risk to the company's ability to produce and deliver its products.
• State of New York Appellate Bond [medium — legal]: The execution of a $1.3 million appellate bond by the State of New York, previously held as restricted cash, impacts the company's liquidity and financial flexibility. While no longer restricted, this represents a significant financial obligation.

Industry Context

STRATA Skin Sciences operates in the medical aesthetics industry, which is characterized by innovation in device technology and increasing consumer demand for non-invasive cosmetic procedures. The market is competitive, with companies vying for market share through product differentiation, clinical validation, and physician adoption. Trends include the integration of AI in device operation and a growing focus on at-home treatment solutions.

Regulatory Implications

The company's operations are subject to regulatory oversight by bodies like the FDA for its medical devices. Compliance with manufacturing standards, marketing claims, and data privacy regulations is crucial. Changes in healthcare policy or reimbursement rates could also impact revenue streams.

What Investors Should Do

1. Monitor revenue trends closely
2. Analyze operating expense management
3. Assess liquidity and cash burn rate
4. Evaluate impact of supply chain risks

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reporting period showing a decline in net revenues and an increase in net loss compared to the prior year.
• 2025-09-30: Cash and cash equivalents as of September 30, 2025 — Reported at $7.076 million, a decrease from $7.261 million at December 31, 2024, indicating reduced liquidity.
• 2025-09-30: Restricted cash as of September 30, 2025 — Reported as $0, down from $1.334 million at December 31, 2024, due to the execution of a $1.3 million appellate bond by the State of New York.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. (STRATA Skin Sciences has an accumulated deficit of $254.463 million as of September 30, 2025, indicating a history of net losses.)

Deferred revenues

Revenue that has been received by a company but not yet earned. (Deferred revenues increased to $2.551 million as of September 30, 2025, from $2.241 million at December 31, 2024, suggesting future revenue recognition.)

Contingent consideration

An additional payment or consideration that is dependent on the occurrence of future events. (The company has current and long-term contingent consideration liabilities, indicating potential future payments related to acquisitions or other agreements.)

Operating lease right-of-use assets

An asset representing the right to use an underlying leased asset for the lease term. (These assets decreased from $1.264 million to $1.005 million, reflecting the company's lease obligations.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, STRATA Skin Sciences has experienced a notable 10.76% decrease in net revenues, falling from $23.986 million to $21.404 million. This revenue decline has contributed to a widening net loss, which increased by 14.25% from $5.531 million to $6.319 million. Gross profit also saw a reduction. While operating expenses decreased overall, this was largely due to a settlement gain in the current period, masking an increase in selling and marketing expenses. New risks related to geopolitical events impacting supply chains have emerged.

Key Financial Figures

• $0.001 — ange On Which Registered Common Stock, $0.001 Par Value SSKN The Nasdaq Stock Marke
• $7.0 thousand — gible employers could qualify for up to $7.0 thousand of credit for each employee based on qu

Filing Documents

• ef20054976_10q.htm (10-Q) — 1736KB
• ef20054976_ex10-1.htm (EX-10.1) — 48KB
• ef20054976_ex31-1.htm (EX-31.1) — 13KB
• ef20054976_ex31-2.htm (EX-31.2) — 12KB
• ef20054976_ex32-1.htm (EX-32.1) — 6KB
• 0001140361-25-042373.txt ( ) — 9669KB
• sskn-20250930.xsd (EX-101.SCH) — 58KB
• sskn-20250930_def.xml (EX-101.DEF) — 329KB
• sskn-20250930_lab.xml (EX-101.LAB) — 519KB
• sskn-20250930_pre.xml (EX-101.PRE) — 341KB
• sskn-20250930_cal.xml (EX-101.CAL) — 46KB
• ef20054976_10q_htm.xml (XML) — 2023KB

Financial Statements

Financial Statements: Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3. Quantitative and Qualitative Disclosure about Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 Part II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 5. Other Information 41 Item 6. Exhibits 42

Signatures

Signatures 42 Certifications Table of Contents

- Financial Information

PART I - Financial Information ITEM 1.

Financial Statements

Financial Statements STRATA Skin Sciences, Inc. and Subsidiary Condensed Consolidated Balance Sheets As of September 30, 2025 and December 31, 2024 (in thousands, except share and per share data) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 7,076 $ 7,261 Restricted cash — 1,334 Accounts receivable, net of allowance for credit losses of $ 538 and $ 433 at September 30, 2025 and December 31, 2024, respectively 3,504 5,253 Inventories 3,058 2,246 Prepaid expenses and other current assets 634 501 Total current assets 14,272 16,595 Property and equipment, net 9,557 10,061 Operating lease right-of-use assets 1,005 1,264 Intangible assets, net 4,223 5,348 Goodwill 1,429 1,429 Other assets 231 231 Total assets $ 30,717 $ 34,928 Liabilities and Stockholders' Equity Current liabilities: Current portion of long-term debt $ 1,875 $ — Accounts payable 2,955 2,433 Accrued expenses and other current liabilities 6,210 7,364 Deferred revenues 2,551 2,241 Current portion of operating lease liabilities 266 328 Current portion of contingent consideration 1,176 1,030 Total current liabilities 15,033 13,396 Long-term debt, net 13,435 15,192 Deferred revenues and other liabilities 199 353 Operating lease liabilities, net of current portion 736 919 Contingent consideration, net of current portion — 96 Total liabilities 29,403 29,956 Commitments and contingencies (Note 15 ) Stockholders' equity: Series C convertible preferred stock, $ 0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding — — Common stock, $ 0.001 par value; 150,000,000 shares authorized; 5,268,708 and 4,171,161 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively. 5 4 Additional paid-in capital 255,772 253,112 Accumulated deficit ( 254,463 ) ( 248,

View Full Filing

View this 10-Q filing on SEC EDGAR